← Back to Search

Pharmacist Coordination of Care for Multiple Chronic Conditions in Cancer Patients

N/A

Recruiting

Research Sponsored by University of Tennessee

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 6 months post-initiation

Awards & highlights

Study Summary

This trial is testing a model of care in which pharmacists coordinate medication, symptom, and disease management for patients with cancer and multiple chronic conditions.

Who is the study for?

This trial is for patients at Vanderbilt University Medical Center with certain blood cancers (CLL/SLL, CML, or MM) who are starting a new oral cancer drug and have at least two other chronic conditions like diabetes or heart failure. They must be taking medication for these conditions and agree to sign informed consent.Check my eligibility

What is being tested?

The study tests a coordinated care approach between oncology and primary care pharmacists to manage medications, symptoms, and diseases in patients with blood cancers and multiple chronic illnesses. It's a pilot study setting the stage for future larger trials.See study design

What are the potential side effects?

Since this trial focuses on pharmacist communication rather than testing new drugs, it doesn't directly involve side effects from interventions. However, managing multiple medications may affect how patients experience their usual treatment side effects.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 6 months post-initiation

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 6 months post-initiation

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months post-initiation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Chronic disease medication adherence

Antineoplastic Agents

Secondary outcome measures

Comprehensive Medication Review (CMR) completion

Oncology pharmacist review of patient-reported outcome measure

Patient-reported outcome measure completion

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Pharmacist Coordinated care Oncology ModelExperimental Treatment3 Interventions

The Pharmacist Coordinated care Oncology Model includes patient self-reported symptoms and medication adherence, comprehensive medication review(s) and intentional communication between oncology and community pharmacists.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

AstraZenecaIndustry Sponsor

4,271 Previous Clinical Trials

288,612,570 Total Patients Enrolled

University of TennesseeLead Sponsor

189 Previous Clinical Trials

141,999 Total Patients Enrolled

Vanderbilt University Medical CenterOTHER

857 Previous Clinical Trials

672,163 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What tangible results is this trial expected to achieve?

"The primary outcome measured over a 6 month period following initiation of medication is the adherence to chronic disease therapy. Secondary objectives include comparing and analysing comprehensive medication reviews conducted by an oncology pharmacist, determining the percentage of comprehensive medication reviews routed to an oncology pharmacist and assessing patient-reported outcomes after oral anticancer agent administration via a designated tool administered at 2 week and 6 week intervals."

Answered by AI

Are there still opportunities to take part in this clinical trial?

"Affirmative. Clinicaltrials.gov records current recruitment for this clinical trial, first uploaded on February 8th 2021 and last updated June 1st 2022. Approximately 30 individuals are being accepted from a single medical centre."

Answered by AI

What is the current participation rate of this experiment?

"Indeed, the information hosted on clinicaltrials.gov corroborates that this medical trial is currently recruiting participants. It was originally published on February 8th 2021 and updated for the last time in June 1st 2022. The study has 30 open slots at a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence

2021. "Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04663100.